Angiotensin II acetate is a Synthetic Peptide owned by La Jolla Pharmaceutical, and is involved in 9 clinical trials, of which 5 were completed, 3 are ongoing, and 1 is planned.

LJPC-501 acts by agonising angiotensin II type I receptor of the renin-angiotensin system. Angiotensin II is central to the renin-angiotensin system which raises blood pressure. In hepatorenal syndrome, renin-angiotensin system is essential in counteracting arterial hypotension. The drug candidate by agonising angiotensin II type I receptor of the renin-angiotensin system helps the kidneys to balance body fluids and electrolytes and also by causing the vasoconstriction of vessels systemically in hepatorenal syndrome.

The revenue for Angiotensin II acetate is expected to reach a total of $1.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Angiotensin II acetate NPV Report.

Angiotensin II acetate is originated and owned by La Jolla Pharmaceutical. Innoviva is the other company associated in development or marketing of Angiotensin II acetate.

Angiotensin II acetate Overview

Angiotensin II acetate (Giapreza) is a naturally occurring peptide hormone derivative act as a vasoconstrictor agent. It is formulated as sterile, aqueous solution and solution concentrate for intravenous route of administration. Giapreza is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock.

It is under development for hypotension in pediatrics. It was also under development for hepatorenal syndrome (HRS).

La Jolla Pharmaceutical Overview

La Jolla Pharmaceutical (La Jolla) discovers, develops and commercializes biopharmaceutical products for life-threatening diseases. The company’s major product includes the US FDA approved Giapreza, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock and Xerava (eravacycline), is an injection of tetracycline class antibacterial for the treatment of complicated intra-abdominal infections (cIAI) in adults. Its investigational product candidates include LJPC-0118 intended for the treatment of severe malaria and LJPC-401, a proprietary formulation of synthetic human hepcidin, an endogenous peptide hormone intended for the prevention of excessive iron accumulation in vital organs. The company sells Giapreza to hospitals in the US through a network of wholesale and specialty distributors. La Jolla is headquartered in San Diego, California, the US.

The company reported revenues of (US Dollars) US$75.7 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$33.4 million in FY2020. The operating profit of the company was US$21.8 million in FY2021, compared to an operating loss of US$35.8 million in FY2020. The net profit of the company was US$19.7 million in FY2021, compared to a net loss of US$39.4 million in FY2020. The company reported revenues of US$10.5 million for the second quarter ended June 2022, an increase of 1.1% over the previous quarter.

Quick View – Angiotensin II acetate

Report Segments
  • Innovator (NME)
Drug Name
  • Angiotensin II acetate
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Cardiovascular
  • Gastrointestinal
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.